Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Shares Outstanding (Weighted Average) (2016 - 2025)

Aptevo Therapeutics' Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $1.9 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 39364.79% year-over-year to $1.9 million; the TTM value through Sep 2025 reached $1.9 million, up 39364.79%, while the annual FY2024 figure was $276137.0, 3574.48% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q3 2025 was $1.9 million at Aptevo Therapeutics, up from $738149.0 in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $5.1 million in Q4 2022 and bottomed at $2852.0 in Q2 2024.
  • The 5-year median for Shares Outstanding (Weighted Average) is $1.5 million (2025), against an average of $2.3 million.
  • The largest annual shift saw Shares Outstanding (Weighted Average) plummeted 99.85% in 2023 before it surged 39364.79% in 2025.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $4.7 million in 2021, then increased by 8.8% to $5.1 million in 2022, then tumbled by 99.85% to $7515.0 in 2023, then surged by 3574.48% to $276137.0 in 2024, then soared by 586.43% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for APVO's Shares Outstanding (Weighted Average) are $1.9 million (Q3 2025), $738149.0 (Q2 2025), and $1.5 million (Q1 2025).